Placeholder Banner

BIO Comments on FDA Draft Guidance on Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations

July 19, 2019

BIO submitted comments on the Food and Drug Administration (FDA) Draft Guidance, Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.

BIO welcomes the guidance on using comparative analytical studies to assess whether a proposed therapeutic protein product is biosimilar to a reference product for purposes of submitting a marketing application under section 351(k) of the Public Health Service (PHS) Act.  In the comments, BIO provides specific changes to clarify the guidance.

Download Full Comments Below
FINAL BIO Comments Comparative Analytical Assessment And Other Quality-Related Considerations
Read the full comments below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…